Negotiations Preempt Subcommittee Markup
The House effort to establish the prominence of state law on product liability issues has already preempted the Energy & Commerce Committee's schedule. The Health Subcommittee had been scheduled to mark up the legislation renewing FDA's user fee and expanding its drug safety authority June 14, but the event was pushed back to June 19 to allow for further negotiation on preemption and other issues.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth